A young Peninsula drugmaker won regulatory approval Friday for a rare-disease drug picked up in a deal two years ago.
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback